small molecule

RIZATRIPTAN BENZOATE

Loss of exclusivity—loss of exclusivity

CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand name	RIZATRIPTAN BENZOATE
Active ingredient	RIZATRIPTAN BENZOATE
Strength	EQ 10MG BASE
Dosage form	TABLET, ORALLY DISINTEGRATING
Route	ORAL
Modality	Small molecule
FDA approval	July 2013
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.